CoChat

Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes

Zhang, Li, MacIsaac, Kenzie D., Zhou, Ting, Huang, Pei-Yu, Xin, Chunlin, Dobson, Jason R., Yu, Kun, Chiang, Derek Y., Fan, Yue, Pelletier, Marc, Wang, Yan, Jaeger, Savina, Krishnamurthy Radhakrishnan, Viveksagar, JeBailey, Lellean, Skewes-Cox, Peter, Zhang, Jing, Fang, Wenfeng, Huang, Yan, Zhao, Hongyun, Zhao, Yuanyuan, Li, En, Peng, Bin, Huang, Alan, Dranoff, Glenn, Hammerman, Peter S., Engelman, Jeffrey, Bitter, Hans, Zeng, Yi-Xin, Yao, Yao · 2017 · Molecular Cancer Research
Cited by 201

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV) associated cancer characterized by a poor prognosis and a high level of lymphocyte infiltrate. Genetic hallmarks of NPC are not completely known but include deletion of the p16 (CDKN2A) locus and mutations in NF-κB pathway components, with a relatively low total mutational load. To better understand the genetic landscape, an integrated genomic analysis was performed using a large clinical cohort of treatment-naïve NPC tumor specimens. This genomic analysis was generally concordant with previous studies; however, three subtypes of NPC were identified by differences in immune cell gene expression, prognosis, tumor cell morphology, and genetic characteristics. A gene expression signature of proliferation was poorly prognostic and associated with either higher mutation load or specific EBV gene expression patterns in a subtype-specific manner. Finally, higher levels of stromal tumor-infiltrating lymphocytes associated with good prognosis and lower expression of a WNT and TGFβ pathway activation signature. Implications: This study represents the first integrated analysis of mutation, copy number, and gene expression data in NPC and suggests how tumor genetics and EBV infection influence the tumor microenvironment in this disease. These insights should be considered for guiding immunotherapy treatment strategies in this disease. Mol Cancer Res; 15(12); 1722–32. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1541-7786.mcr-17-0134

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 201

Metadata

Authors
Zhang, L., MacIsaac, K. D., Zhou, T., Huang, P.-Y., Xin, C., Dobson, J. R., Yu, K., Chiang, D. Y., Fan, Y., Pelletier, M., Wang, Y., Jaeger, S., Krishnamurthy Radhakrishnan, V., JeBailey, L., Skewes-Cox, P., Zhang, J., Fang, W., Huang, Y., Zhao, H., Zhao, Y., Li, E., Peng, B., Huang, A., Dranoff, G., Hammerman, P. S., Engelman, J., Bitter, H., Zeng, Y.-X., & Yao, Y.
Venue
Molecular Cancer Research
Published
2017-11-30
Volume
15
Issue
12
Pages
1722-1732
ISSN
  • 1541-7786 (ISSN-L)
  • 1557-3125
OpenAlex
W2752300866
Cited by
201
References
10
FWCI
7.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-17-0134
The paper
Zhang, L., MacIsaac, K. D., Zhou, T., Huang, P.-Y., Xin, C., Dobson, J. R., Yu, K., Chiang, D. Y., Fan, Y., Pelletier, M., Wang, Y., Jaeger, S., Krishnamurthy Radhakrishnan, V., JeBailey, L., Skewes-Cox, P., Zhang, J., Fang, W., Huang, Y., Zhao, H., . . . Yao, Y. (2017). Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-17-0134

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.